home / stock / crnx / crnx news

CRNX News and Press, Crinetics Pharmaceuticals Inc. From 03/14/22

Stock Information
Company Name: Crinetics Pharmaceuticals Inc.
Stock Symbol: CRNX
Market: NASDAQ
Website: crinetics.com
Menu
CRNX CRNX Quote CRNX Short CRNX News CRNX Articles CRNX Message Board
Get CRNX Alerts

News, Short Squeeze, Breakout and More Instantly...
CRNX - Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a...
CRNX - Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a...

CRNX - Crinetics, Sanwa ink licensing deal for cancer/hormonal disorder drug in Japan

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Japna's Sanwa Kagaku Kenkyusho are collaborating to exclusively develop and commercialize Crinetics' investigational drug paltusotine in Japan. Paltusotine is being evaluated to treat acromegaly and neuroendocrine tumors (NETs), including NETs ...

CRNX - Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tum...
CRNX - Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...

CRNX - Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling stud...

CRNX - Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today an...
CRNX - Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced toda...

CRNX - Crinetics Pharmaceuticals Inc.: The Winning Streak Continues (CRNX)

Shares of Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at $28.73, eclipsing its 52-week high. So far today approximately 223,000 shares have been exchanged, as compared to an average 30-day volume of 302,000 shares. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceu...

CRNX - Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced toda...
Previous 10 Next 10